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Abstract 
Antibodies against citrullinated proteins/peptides (ACPA), especially antibodies targeting mutated 
citrullinated vimentin (anti-MCV), are novel biomarkers of rheumatoid arthritis (RA). While ACPAs 
are specific and sensitive markers for RA, there have been hardly any reports regarding ACPAs in 
psoriatic arthritis (PsA) and psoriasis without joint symptoms (PSO). The aim of the present study 
was to investigate the prevalence of anti-MCV antibodies in PsA and PSO. Serum anti-MCV titres 
were measured in 46 PsA and 42 PSO patients, and in 40 healthy controls. Anti-MCV levels were 
assayed using a commercial enzyme-linked immunosorbent assay (ELISA). Serum autoantibody 
levels were correlated with several clinical and laboratory parameters. Anti-MCV antibody levels in 
PsA patients were significantly higher than titres in the PSO group. Among the clinical variables, the 
presence of tender knee joints and nail psoriasis was significantly associated with anti-MCV 
positivity in PsA patients. Higher anti-MCV titers in PSO patients were associated with more severe 
disease course, and with early onset of psoriatic skin symptoms. Our results suggest that anti-MCV 
antibodies can be used as novel markers in the diagnosis of psoriatic arthritis, and in a subset of 
psoriasis patients. 
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1.  Introduction 
Antibodies targeting mutated citrullinated vimentin (MCV) belong to the group of anti-citrullinated 
protein/peptide antibodies (ACPAs). Detection of ACPA titres is a novel specific and sensitive 
marker for diagnosing rheumatoid arthritis (RA) [1-5]. Furthermore, ACPAs have important 
prognostic relevance as well: higher ACPA levels are associated with faster progression and poorer 
outcome in RA [6-9]. Novel members of the ACPA group are the antibodies against citrullinated 
cyclic peptides (anti-CCP). The anti-CCP antibodies seemed to fulfil the requirements of an ideal 
marker in the diagnosis of early RA. Recently, antibodies targeting mutated citrullinated vimentin 
(anti-MCV) were found to have even higher diagnostic sensitivity than anti-CCP and rheuma factor 
tests in RA [10-12]. Anti-MCV antibodies are detectable in early RA patients, even before 
symptoms are manifest, thus, they are supposed to have important prognostic value. Several recent 
studies suggest that the production of these autoantibodies is associated with faster disease 
progression, and seems to be a useful predictive marker of severe joint damage [6, 13]. Anti-MCV 
antibodies target the citrullinated vimentin. Vimentin is the main cytoskeletal component of the 
mesenchymal cells [14, 15]. It is not coded by DNA, it can only be expressed by post-translational 
modification. The post-translational modification is the enzymatic citrullination of the amino acid 
arginine. Vimentin contains 43 arginine residues, and the citrullination is catalyzed by the enzyme 
peptidylarginine deiminase (PAD or PADI). PAD enzymes can be found in monocytes and 
macrophages. Tissue inflammation and cell apoptosis changes the structure of the protein by 
enzymatic citrullination, and activate the immune system by the increased production of 
autoantibodies [16]. Recent studies suggest that the enzymatic citrullination and the production of 
ACPAs also can be associated with other inflammative arthritis associated autoimmune diseases [17-
19]. 
Psoriatic arthritis (PsA) is a seronegative spondyloarthropathy developing in up to 30 percent of 
patients with psoriasis (National Psoriasis Foundation, www.psoriasis.org). PsA occurs more 
frequently in patients with HLA-B27 haplotype [20-22]. PsA has several different clinical 
phenotypes: oligoarticular, polyarticular, symmetrical and asymmetrical peripheral joint 
inflammation or axial involvement [23, 24]. Several different system and criteria exist to aid the 
diagnosis and classification of PsA [21, 25-29]. Although none of them are unequivocally accepted, 
the Moll and Wright [29] described classification criteria and more recently the classification criteria 
for psoriatic arthritis (CASPAR) have been used most frequently [28]. The wide spectrum of disease 
expression makes it often difficult to distinguish PsA from rheumatoid arthritis (RA) or other 
spondylarthropathies. Currently, there is no specific test that could be used in the diagnosis of PsA. 
Moreover, a biomarker (or biomarkers) that could distinguish between different clinical phenotypes 
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of PsA or PsA and psoriasis vulgaris, or could be used as a predictive marker for future PsA 
development in psoriasis patients, is still lacking. 
Because of the several clinical similarities between PsA and RA, and because of the fact that the 
anti-MCV antibodies are highly sensitive markers in RA, we aimed to investigate the prevalence of 
anti-MCV antibodies in PsA and PsO patients. Furthermore, associations between the anti-MCV 
antibody titres and the clinical and laboratory variables of PsA and PsO patients were also studied. 
2. Materials and Methods  
2.1. Study population.  
This clinical study was approved by the Regional and Institutional Human Medical Biological 
Research Ethics Committee of the Albert Szent-Györgyi Clinical Center, University Of Szeged. 
Informed consent was obtained from all participants in the study.  
In the psoriatic arthritis (PsA) group we studied 46 patients, 24 women and 22 men, seen at the 
Department of Rheumatology and at the Department of Dermatology and Allergology of the 
University of Szeged (Szeged, Hungary), for psoriatic arthritis. Basic demographic and clinical 
characteristics of PsA group are summarized in Table 1. The mean (± standard deviation; SD) age of 
patients was 54.3 ± 11.9 years (range: 28-77 years). At the time of sampling collection the mean 
DAS28 score was 4.51 ± 1 (range: 2.08-6.81); 33 (72%) patients’ scores were lower or equal to 5.1 
(low PsA activity), whereas 13 (28%) had DAS28 scores higher than 5.10 (high PsA activity). All 
patients were previously or currently treated with at least one type of disease-modifying 
antirheumatic drug (DMARD). The group was heterogeneous regarding arthritis phenotypes. We 
used the Moll and Wright criteria [29] to classify PsA patients into five subgroups. Twenty five 
patients (54%) had asymmetrical oligoarthritis, 20 patients (43%) had symmetrical polyarthritis, 8 
patients (17%) had axial type of arthritis, and 2 patients (4%) had distal arthritis. There was only 1 
patient having arthritis mutilans (2%). Fifteen PsA patients (33%) had distal interphallangeal (DIP) 
joint inflammation. All patients had psoriatic skin lesion as well. Detailed clinical and laboratory 
characteristics of patients in the PsA group are shown in Table 2.  
Forty two patients with psoriasis vulgaris (PsO), treated at the Department of Dermatology and 
Allergology, University of Szeged, were enrolled in the study. Basic demographic and clinical 
characteristics of psoriasis group without arthritis are shown in Table 1. The mean age was 45.60 ± 
15.72 years (range: 18-78 years), and the female:male ratio was 11:31 (26% vs. 74%). The group 
consisted of 6 patients with mild and 36 patients with severe disease course. Assessment of disease 
course severity was based on previous and concomitant antipsoriatic therapies: patients previously or 
currently treated with systemic (including biological) therapy or full body phototherapy were 
considered severe psoriasis patients, whereas others were considered as having a mild disease 
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course. At the time of serum sample collection the mean Psoriasis Area and Severity Index (PASI) 
score was 5.84 ± 6.75 (range: 0.00-34.20), however, most patients were on concurrent systemic, 
biological or phototherapy. None of the patients had psoriatic joint involvement, as assessed by a 
trained rheumatologist. Clinical and laboratory characteristics of PsO patients are summarized in 
Table 2.  
A randomly selected, self-stated healthy group of volunteers (N=40) served as control (none of 
them had ever psoriatic skin or joint symptoms). The mean age was 45.05 ± 19.56 years (range: 16-
82 years) and the female:male ratio was equal (20 vs. 20). 
 
2.2. Detection of anti-MCV IgG by ELISA. The anti-MCV IgG antibodies were analysed by ELISA 
(ORG 548 anti-MCV; Orgentec Diagnostika GmbH, Mainz, Germany), which contains recombinant 
MCV as antigen. The analysis was conducted according to the manufacturer’s instructions for use. 
Patients with anti-MCV titers higher than the 20 U/ml cut-off value, as recommended by the 
manufacturer, were considered being positive. 
 
2.3. Statistical analysis. The associations between the antibody levels and different clinical 
parameters were analysed by non-parametric (Mann-Whitney u test) and correlation (Spearman's 
rho) tests. The associations between the anti-MCV positivity and the clinical features were compared 
by Fischer exact test and correlations (Spearman's rho). P values <0.05 were considered significant. 
All statistical analyses were performed using the statistical program SPSS Windows (v15.0). 
3. Results 
3.1. Anti-MCV titers are significantly higher in PsA than in PsO patients and non-psoriatic 
individuals. As anti-MCV positivity is a characteristic hallmark of rheumatoid arthritis, first we 
analysed whether anti-MCV antibodies are also associated with a different type of inflammatory 
joint disease, psoriatic arthritis. PsA patients had significantly higher mean serum anti-MCV levels 
than patients with only skin manifestations of psoriasis (Figure 1). The mean autoantibody level of 
the PsA group was 30.32 ± 82.14 U/ml compared to 8.71 ± 7.41 U/ml in the PSO group. Statistically 
significant difference was not detected between the mean antibody levels in the control (9.50 ± 4.23 
U/ml) and the PSO group. 
When patients were subdivided into anti-MCV positive and anti-MCV negative populations, 
based on the recommended cut-off value ( > 20 U/ml),  11 PsA patients (24%) and 3 PsO patients 
(8%) were found to be positive for anti-MCV, whereas all of the controls were anti-MCV negative. 
The differences between the PsA and PsO groups, as well as the PsA and control groups were found 
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statistically significant (P = 0.032 and P = 0.0009, respectively). Statistically significant difference 
was not detected between the PsO and the control groups (P = 0.0848). 
 
3.2. Higher anti-MCV titer in PsO patients is associated with more severe disease course. When 
psoriasis patients were subdivided into severe (previously or currently treated with systemic or 
phototherapy) and mild (never received systemic or phototherapy) groups, higher anti-MCV 
antibody titers were significantly associated with more severe disease course (9.73 ± 7.54 U/ml vs. 
2.73 ± 2.37 U/ml, P = 0.033) (Figure 2). Furthermore, we found that severe PsO patients treated with 
biological therapy (Figure 3) had significantly higher anti-MCV levels than severe psoriasis patients 
not requiring biological therapy (14.01 ± 6.22 U/ml vs. 3.01 ± 3.34 U/ml, P < 0.01). It seems, 
therefore, that present psoriasis activity is not a critical determinant of anti-MCV level. Rather, 
patients with the most severe disease course - and thus requiring biological therapy - have the 
highest anti-MCV levels among PsO patients. A similar analysis in the PsA group was not feasible, 
as the group almost entirely consisted of severe psoriatic arthritis patients receiving systemic 
DMARD or biological therapy. Similarly to the PsO group, current disease activity, as demonstrated 
by the DAS28 level, was not associated with higher anti-MCV levels in the PsA group either (P = 
0.843, data not shown). 
 
3.3. High anti-MCV titers in psoriasis are associated with early onset of disease. Psoriasis patients 
can be subdivided into two distinct groups based on the first onset of skin symptoms. Patients with 
early onset (below 30 years of age) psoriasis usually have stronger genetic background (HLA-cw6), 
and among others, more frequently develop psoriatic arthritis [30, 31]. Therefore, next we analysed, 
whether an association between the age at onset of psoriasis and the level of anti-MCV antibody 
titers exist. As demonstrated in Figure 4, anti-MCV levels are in significant inverse correlation with 
the age at the onset of psoriasis (P = 0.019), namely, patients with early appearance of psoriatic skin 
symptoms usually present with higher anti-MCV levels than patients with late disease onset. When 
the same analysis was carried out in the PsA group, no correlation was found between the age of 
arthritis onset and the level of anti-MCV serum level (P = 0.096, data not shown). 
 
3.4. The presence of tender knee joints and nail psoriasis is associated with anti-MCV positivity in 
PsA patients. In order to find clinical or laboratory features associated with high anti-MCV levels, 
we next correlated a detailed set of parameters with anti-MCV positivity in psoriatic arthritis 
patients.  PsA patients were subdivided into anti-MCV positive and negative groups, using the 
recommended cut-off value (>20 U/ml). The list of studied parameters is shown in Table 3. A 
similar experiment, although seemingly reasonable, was not feasible in the PsO group, as the low 
number of anti-MCV positives (N = 3) did not allow fair statistical analysis in this group.  
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Among all parameters analysed in the PsA group, only two proved to be correlated with high 
anti-MCV titers. The presence of painful knee joints was significantly more frequent in anti-MCV 
positive patients (63.64% vs. 25.71%, P = 0.032).  When anti-MCV titers in PsA patients with or 
without the presence of painful knees were compared, significantly higher mean antibody titer was 
detected in the group with painful knees (61.18 ± 133.76 U/ml vs. 13.87 ± 20.22 U/ml, P = 0.013) 
(Figure 5). There was no correlation, however, between presence of painful knees and either the 
patient’s age or the patient’s body weight (data not shown).  
The second clinical feature significantly more frequently appearing in the anti-MCV positive 
PsA group was the presence of nail psoriasis (63.64% and 17.14% in patients with and without 
psoriatic nail symptoms, respectively, P = 0.006). However, when PsA and PsO patients were 
subdivided based on the presence of nail symptoms, although a clear trend was observed towards an 
increased anti-MCV level in PsA patients with nail symptoms, the difference was not statistically 
significant (Figure 6).  
4. Discussion 
In this study, we have demonstrated that anti-MCV titers are significantly higher in psoriasis patients 
with arthritis than in psoriasis patients without arthritis or in healthy controls. The mean 
autoantibody level in the PsA group was 30.3 U/ml compared to 8.7 U/ml in the PSO, and 9.5 U/ml 
in the control group. Serum anti-MCV concentrations, although clearly elevated in a subset of PsA 
patients, were markedly lower than the several hundred-to-thousand U/ml values reported previously 
in RA patients [32]. Similar to our observations, modestly elevated anti-MCV titers were reported 
previously in a subpopulation of PsA [12, 33], as well as, more recently, in ankylosing spondylitis 
(AS) patients [34]. In our study cohort, 24% (11 out of 46) of PsA patients were found to be anti-
MCV positive. To our knowledge, anti-MCV levels in PsA have been reported only 2 times 
previously, and the results are not in full concordance. In these reports the prevalence of anti-MCV 
antibodies in PsA ranges from 3.6% [33] to 15.2% [12]. The cause of the even higher percentage of 
anti-MCV positivity in our study population cannot be fully explained. Anti-MCV antibody titers 
were previously reported to significantly correlate with disease activity in rheumatoid arthritis [11, 
13]. In our anti-MCV positive patients, however, the average number of swollen joints was not very 
high (3.45 ± 2.94), disease activity according to DAS28 score was moderate (4.49 ± 0.98). Thus, in 
our study population, anti-MCV reactivity was not associated with high disease activity; however, 
our patients were all actively treated with DMARDs or biologicals at the time of sample collection.  
When clinical and laboratory features were correlated with anti-MCV levels, nail psoriasis and 
tender knee joints were observed significantly more frequently in anti-MCV positive PsA patients 
than in anti-MCV seronegatives (64% vs. 17%). It has recently been recognized that distal 
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interphalangeal (DIP) joint disease in PsA is associated with diffuse inflammation that envelops the 
nail root and adjacent bone [35]. Thus, nail matrix inflammation, and, therefore, psoriatic nail 
changes are resulting from PsA enthesitis, and consequently, nail psoriasis reflects DIP joint 
enthesitis. More recently, it has been shown that nail involvement in psoriasis is directly correlated 
with systemic enthesitis, as enthesopathy scores are significantly higher in PsA patients with nail 
disease than in patients without nail disease [36]. Taken together, the association of anti-MCV 
positivity with psoriatic nail symptoms in our study population may indicate that high anti-MCV 
level is a marker of systemic enthesitis in PsA. However, we could not confirm this hypothesis by 
directly correlating enthesopathy scores with anti-MCV titers, as the presence of subclinical 
enthesitis was not recorded at the time of sample collection in this study. Whether the increased 
number of PsA patients with tender knee joints within the group of anti-MCV seropositives is an 
epiphenomenon, or represents a clear pathogenetic association, requires further investigations.  
Although the mean anti-MCV titers of psoriasis patients without arthritis did not differ from that 
detected in healthy controls, when psoriasis patients without arthritis were divided into severe and 
mild groups, higher anti-MCV antibody titers were significantly associated with more severe disease 
course (Figure 2). Furthermore, patients treated with biological therapy had significantly higher anti-
MCV levels than severe psoriasis patients not requiring biological therapy (Figure 3). These findings 
imply that within the group of non-arthritic psoriasis patients, higher anti-MCV levels may 
distinguish patients with more severe disease course. Whether these patients have significant 
subclinical joint involvement, potentially detectable with highly sensitive imaging methods, is 
unclear. Furthermore, we cannot exclude the possibility that these patients would, in the future, 
develop clinically evident psoriatic arthritis. Concerning the role of (biological) therapy in ACPA 
levels, some studies have reported significantly decreased RF and anti-CCP serum levels in RA 
patients, as an effect of 6-12 months of TNF inhibitor therapy [37-39]. Roland et al. found 
significantly decreased anti-MCV antibody levels after 18-24 months of anti-TNF treatment in RA 
[40]. Several other studies, however, did not report marked changes in the anti-CCP levels after 22, 
30 and 54 weeks of infliximab treatment in rheumatoid arthritis [41-43]. These studies indicate that 
anti-CCP antibodies are not influenced by anti-TNF-α therapy, and are qualitatively stable hallmark 
of RA. Even though a definite conclusion cannot be drawn from these findings, considering the 
relatively low overall anti-MCV titers in the PsO population, in seems unlikely that biological 
treatment would significantly modify (or even increase) the anti-MCV antibody levels. Therefore, 
the increased antibody titers in the group of psoriasis patients treated with biological therapy are, in 
our opinion, not directly related to the treatment, but to the underlying severe disease course leading 
to the use of biologicals. The idea that more severe disease course in psoriasis is associated with 
higher anti-MCV levels, was further supported by the finding that anti-MCV levels are in significant 
inverse correlation with the age at the onset of psoriatic skin symptoms (Figure 4). It is well known 
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that patients with early onset psoriasis usually have stronger genetic background (HLA-cw6), and 
among others, more frequently develop psoriatic arthritis [30, 31]. Also, early onset psoriasis is 
frequently associated with more severe disease course, thus patients with early onset psoriasis are 
potentially more likely to suffer from psoriatic arthritis and from more severe skin symptoms.  
In conclusion, our study suggests that anti-MCV antibodies, apart from being biomarkers of 
early RA, can also be used to differentiate a subset of PsA patients from psoriasis patients without 
arthritis. As differentiating in early and mild forms of PsA can present significant challenge in some 
cases, detection of anti-MCV positivity can aid the diagnosis of PsA, especially in patients with 
psoriatic nail symptoms and tender knee joints. Furthermore, high levels of anti-MCV in psoriasis 
patients without clinically manifest arthritis may also distinguish patients who are more likely to run 
a severe disease course, and potentially require biological therapy. However, this study needs to be 
expanded on a large group of PsA and psoriasis patients to confirm these associations.
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TABLE 1: Basic demographic and clinical characteristics of Psoriatic Arthritis (PsA) and Psoriasis 
(PsO) groups. 
  
Variable Psoriatic Arthritis (N = 46) Psoriasis (N = 42) 
 
 
Male : female ratio 24 : 22 31 : 11 
 
 
Age (mean ± SD; years) 54.35 ± 11.87 45.60 ± 15.72 
 
 
BMI (mean ± SD; kg/m2) 29.38 ± 6.41 28.86 ± 9.80 
 
 
Current smokers (%) 20% 12% 
 
 
Age at diagnosis of PsO (mean ± SD; years) 38.91 ± 14.47 28.84 ± 15.82 
 
 
Age at diagnosis of PsA (mean ± SD; years) 45.26 ± 13.80 − 
 
 
Disease scored severity (mild : severe) 0 : 46 6 : 36 
 
 
Psoriasis guttata (%) 4% 20% 
 
Arthritis mutilans (%) 2% − 
 
 
Axial type of arthritis (%) 17% − 
 
 
Distal type of arthritis (%) 4% − 
 
 
Asymmetrical oligoarthritis (%) 54% − 
 
 
Symmetrical polyarthritis (%) 43% − 
 
Therapy   
 
 
 Received MTX therapy (%) 85% 57% 
 
 
 Received systemic steroid treatments (%) 13% 2% 
 
 
 Received 311nm NB- UVB therapy (%) 7% 38% 
 
 
 Received PUVA therapy (%) 2% 31% 
 
 
 Received biological therapy (%) 13% 52% 
 
 
PsO: psoriasis vulgaris, PsA: psoriatic arthritis, BMI: body mass index, MTX: methotrexate, PUVA: psoralen + ultraviolet A, 311nm NB- 
UVB: 311nanometer narrow-band ultraviolet B. Symmetrical arthritis: two side arthritis in frequency more than 50%. 
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TABLE 2: Clinical and laboratory characteristics of patients in the Psoriatic Arthritis (PsA) and 
Psoriasis Vulgaris (PsO) groups 
  
Variable Psoriatic Arthritis (N = 46) Psoriasis (N = 42) 
 
 
ANTI-MCV positivity (%) 24% 8% 
 
 
Level of ANTI-MCV (mean ± SD; U/ml) 30.32 ± 82.14 8.71 ± 7.41 
 
 
ANA positivity (%) 38% not measured 
 
 
RF positivity (>9 U/ml; %) 11% not measured 
 
 
Active psoriatic lesions in the skin 100% 95% 
 
 
 PASI score (mean ± SD) − 5,84 ± 6,75 
 
 
 Nail psoriasis (%) 28% 43% 
 
 
 Scalp psoriasis (%)  72% 57% 
 
 
 Plaques on the face (%) 11% 14% 
 
 
 Plaques on the upper limbs (%) 61% 71% 
 
 
 Plaques on the trunk (%) 30% 48% 
 
 
 Plaques on the perineum (%) 15% 7% 
 
 
 Plaques on the lower limbs (%) 59% 88% 
 
 
Arthritic features   
 
 
 DAS28 score (mean ± SD) 4.51 ± 1.00 − 
 
 
 DIP involvement (%) 33% − 
 
 
 Erosion (%) 24% − 
 
 
 Tender joint count (mean ± SD) 9.78 ± 5.90 − 
 
 
  Back (%) 48% − 
 
 
  Shoulders (%) 37% − 
− 
 
  Elbows (%) 15% − 
 
 
  Wrists (%) 46% − 
 
 
  Hands (%) 67% − 
 
 
  Hip (%) 17% − 
 
 
  Knees (%) 35% − 
 
 
  Foot (%) 61% − 
 
  Swollen joint count (mean ± SD) 2.67 ± 3.19 − 
 
   Swollen shoulder (%) 0% − 
 
   Swollen elbow (%) 2% − 
 
   Swollen wrist (%) 9% − 
 
   Swollen hand (%) 43% − 
 
   Swollen hip (%) 0% − 
 
    Swollen knee (%) 11% − 
 
   Swollen feet (%) 26% − 
 
 
Anti- MCV: antibodies against mutated citrullinated vimentin, ANA: anti-nuclear antibody, RF: rheuma factor, DIP: distal 
interphallangeal, PASI:  psoriasis area and severity index, DAS28: disease activity score. 
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FIGURE 1: Anti-MCV titers are higher in PsA patients than in patients with psoriasis without arthritis and in healthy 
volunteers. The plots show the antibody levels of the investigated patients. The horizontal lines represent 
the mean levels of anti-MCV antibodies. The mean autoantibody level of the PsA group was 30.32 ± 82.14 
U/ml compared to 8.71 ± 7.41 U/ml in the psoriasis and 9.50 ± 4.23 U/ml in the control group. *There was 
statistically significant difference between the PsA and the psoriasis groups (P < 0.05). 
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   FIGURE 2:  Anti-MCV titers are higher in patients with severe psoriasis than in mild psoriasis. The plots show the anti-
MCV levels in severe (previously or currently treated with systemic or phototherapy) and mild (never received 
systemic or phototherapy) PsO patients. The horizontal lines represent the mean levels of anti-MCV antibodies. 
*Significant difference was detected between the mild and the severe psoriasis patients’ groups (2.73 ± 2.37 
U/ml vs. 9.73 ± 7.54 U/ml, P < 0.05). 
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FIGURE 3: Anti-MCV titers are higher in severe PsO patients treated with biological therapy than in severe psoriasis 
patients not requiring biological therapy. The plots show the antibody levels of investigated patients. The 
horizontal lines represent the mean levels of anti-MCV antibodies. *PsO patients not requiring biological 
therapy had significantly lower anti-MCV levels than severe psoriasis patients treated with biological 
therapy (3.01 ± 3.34 U/ml vs. 14.01 ± 6.22 U/ml, P < 0.01). 
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FIGURE 4: Anti-MCV levels are in significant inverse correlation with the age at the onset of psoriasis in psoriasis  
patients. The plots represent the anti-MCV levels of the psoriasis patients and the age at the onset of psoriasis. 
(P = 0.019) 
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Variable Anti-MCV positive PsA patients (N = 11) Anti-MCV negative PsA patients (N = 35) 
 
 
Sex ratio (male : female) 3 : 8 21 : 14 
 
 
Age (mean ± SD; years) 57.91 ± 9.26 53.23 ± 12.48 
 
 
Current smoker (%) 9% 23% 
 
 
Age at diagnosis of PsO (mean ± SD; years) 44.27 ± 13.73 37.23 ± 14.48 
 
 
Age at diagnosis of PsA (mean ± SD; years) 46.55 ± 15.78 44.86 ± 13.34 
 
 PsA scored severity (mild : severe) 0 : 11 0 : 35   
 Psoriasis guttata (%) 9% 3%  
 Arthritis mutilans 9% 0%  
 Axial type (%) 27% 14%  
 Distal type (%) 9% 3%  
 Asymmetrical oligoarthritis (%) 64% 51%  
 Symmetrical polyarthritis (%) 36% 46%  
 Therapy    
 
 
Received local steroid treatments (%) 73% 83% 
 
 
 
Received sulfasalazine (%) 27% 20% 
 
 
 
Received systemic steroid treatments (%) 27% 9% 
 
 
 
Received 311nm NB-UVB therapy (%) 18% 3% 
 
  Received PUVA therapy (%) 0% 3%  
 
 
Received MTX therapy (%) 73% 89% 
 
 
 
Received biological therapy (%) 18% 11% 
 
 
 
DIP involvement (%) 18% 37% 
 
 
 
Erosion (%) 18% 26% 
 
 Level of ANTI-MCV (mean ± SD; U/ml) 102.41 ± 150.99                7.67 ± 3.77         *  
 ANA positivity (%) 50% 33%  
 RF positivity (%) 0% 14%  
 DAS28 score (mean ± SD) 4.49 ± 0.98 4.52 ± 1.02  
 Psoriatic skin lesions    
  Nail psoriasis (%) 64%                 17%             *  
  Scalp psoriasis (%) 64% 74%  
  Plaques on the face (%) 9% 11%  
  Plaques on the upper limbs (%) 55% 63%  
  Plaques on the trunk (%) 36% 29%  
  Plaques on the perineum (%) 9% 17%  
  Plaques on the lower limbs (%) 55% 60%  
 Arthritic features    
 
 Tender joint count (mean ± SD) 7.27 ± 3.58 10.57 ± 6.29 
 
   Back (%) 36% 51%  
 
 
 
Shoulders (%) 36% 37% 
 
 
 
 
Elbows (%) 18% 14% 
 
 
 
 
Wrists (%) 45% 46% 
 
 
 
 
Hands (%) 45% 74% 
 
 
 
 
Hip (%) 0% 23% 
 
 
 
 
Knees (%) 64%                 26%             * 
 
 
 
 
Foot (%) 73% 57% 
 
  Swollen joint count (mean  ± SD) 3.45 ± 2.94 2.43 ± 3.27  
   Swollen shoulder (%) 0% 0%  
   Swollen elbow (%) 9% 0%  
   Swollen wrist (%) 18% 6%  
   Swollen hand (%) 45% 40%  
   Swollen hip (%) 0% 0%  
   Swollen knee (%) 27% 6%  
   Swollen feet (%) 18% 29%  
 
PsO: psoriasis vulgaris, PsA: psoriatic arthritis, Anti- MCV: antibodies against mutated citrullinated vimentin, BMI: body mass index, PASI: psoriasis area and severity 
index, DAS28: disease activity score, DIP: distal interphallangeal, HLA B27: human leukocyte antigen B27, ANA: anti-nuclear antibodies, RF: rheuma factor, ESR: 
erythrocyte sedimentation rate, CRP: C- reactive protein, MTX: methotrexate, PUVA: psoralen + ultraviolet A, nm: nanometer.  Symmetrical arthritis: two side arthritis 
in frequency more than 50%. The current values in these cases at least in 60% were completed. In case of other values, the datas were complete, 100%. * There were 
significant differences between the anti-MCV positive and negative groups (P < 0.05). 
 
TABLE 3: Comparisons of clinical ﬁndings between anti-MCV positive versus anti-MCV negative PsA patients. 
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FIGURE 5: The anti-MCV levels of PsA and PsO patients with and without nail psoriasis. The plots show the antibody 
levels of PsA and PsO patients with and without nail psoriasis. The horizontal lines represent the mean levels of 
anti-MCV antibodies. Significant correlations were not found between the groups. 
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FIGURE 6: The anti-MCV levels in PsA patients with painful knees are significantly higher than in patients without 
painful knee. The plots show the antibody in PsA patients without pain of knees (labelled as “NO”) and with 
pain of knees (labelled as “YES”). The horizontal lines represent the mean levels of anti-MCV antibodies. * 
There was significant difference of anti-MCV levels between the two groups (13.87 ± 20.22 U/ml vs. 61.18 ± 
133.76 U/ml, P < 0.05). 
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